# IAP20 Rec's PCT/PTO 31 MAR 2006 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE

International Application No. : PCT/EP2004/010396

International Filing Date : September 16, 2004

Priority Date(s) Claimed : October 1, 2003

Applicant(s) (DO/EO/US) : Simon GOODMAN et al.

Title: ALFAVBETA3 AND ALFAVBET6 INTEGRIN ANTAGONISTS AS ANTIFIBROTIC AGENTS

### INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

This information disclosure statement is made in accordance with 37 C.F.R. §§ 1.56, 1.97 and 1.98 as follows:

#### Timing and Fees

$\boxtimes$	Under 37 C.F.R. § 1.97(b), no fee or statement is required for filing this information disclosure statement is filed:				
		within three months of the filing date of a national application other than a CPA under § 1.53(d);			
	$\boxtimes$	within three months of the actual filing date of the national phase of a PCT application; OR			
		before the mailing of a first substantive office action (including after filing of an RCE).			
		37 C.F.R. § 1.97(c), this information disclosure statement is filed after the periods ied in 37 C.F.R. § 1.97(b), but before the mailing date of:			
		a final rejection under 37 C.F.R. 1.113; termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2); OR a notice of allowance under 37 C.F.R. § 1.311; and			

		is acco	empanied by:
			the statement as specified in 37 C.F.R. § 1.97(e) set out below; OR
			a check covering the fee of \$180.00 under 37 C.F.R. § 1.17(p).
			R. § 1.97(d), this information disclosure statement is filed after the mailing lowing actions which have not been withdrawn:
		a final	action under 37 C.F.R. § 1.113;
		termin	ation of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2);
		OR a r	notice of allowance under 37 C.F.R. § 1.311;
	AND i	s filed o	on or before payment of the issue fee; AND is accompanied by:
			tement as specified in 37 C.F.R. § 1.97(e) as set forth below, and the fee of 0 under 37 C.F.R. § 1.17(p).
Statem	ents Ur	nder 37	C.F.R. 1.97(e)
			Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application having a mailing date not more than three months prior to the filing date of this information disclosure statement; or
			No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned attorney after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing date of the information disclosure statement.
Cited I	Material	<u>s</u>	
		ancesto	of materials listed but not attached were cited in benefit (35 U.S.C. § 120) or application Serial No, on Form 892 by the Examiner and/or Form y the applicant; see 37 C.F.R. § 1.98(d).
	$\boxtimes$	-	of materials listed but not attached were cited in an international search dated <u>January 20, 2005</u> .
		Not red	quired by 37 CFR § 1.98.
		Copies	of the materials listed are attached (except for the foregoing).

Non-E	English ]	Language References
	$\boxtimes$	An English-language search report or equivalent paper from a foreign patent office is provided indicating the relevance of the cited reference(s).
		A foreign-language search report from a foreign patent office is provided, and pertinent parts are translated substantively below:
		X = document of particular relevance when it is taken alone
		Y = document of particular relevance when it is combined with another such document
		A = document defining the general state of the art
		O = non-written disclosure
,		P = intercalated document
		T = document cited to understand the theory or principle underlying the invention
		E = patent document which has the benefit of a date earlier than the filing date and which was published only on or after this filing date
		D = cited in the application
		L = cited for another reason
		& = publication of member of same patent family
		Translation of other relevant information on foreign search report
		[insert necessary translation here]
Other	Informa	ition
		·
Payme	ent of Fe	ees Due (If Any):
	A chec	ek for \$ covering the fee identified above is attached.
	Please	charge to Deposit Account No. 13-3402 \$ for the fee identified above.

## IAP20 Res'd PCT/PTO 31 MAR 2006

The Commissioner is hereby authorized to charge or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,

Anthony J. Zelano, Reg. No. 27,969

Attorney for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
Arlington Courthouse Plaza I
2200 Clarendon Blvd. Suite 1400
Arlington, Virginia 22201
Telephone: (703) 243-6333
Facsimile: (703) 243-6410

Attorney Docket No.: MERCK-3151

Date: March 31, 2006

AJZ:aap

K:\Merck\3000 - 3999\3151\Information Disclosure Statement.doc

## IAP20 Rec'd PCT/PTO 31 MAR 2006

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known			
				Application Number	Unassigned 57/215		
INFO	RMATION	I DIS	CLOSURE	Filing Date	March 31,m2006 4		
STAT	EMENT B	BY AF	PPLICANT	First Named Inventor	Simon GOODMAN et al.		
				Group Art Unit	Unassigned		
(	use as many sh	neets as	necessary)	Examiner Name	Unassigned		
Sheet	1	of	1	Attorney Docket Number	MERCK-3151		

	U.S. PATENT DOCUMENTS						
Examiner Initials *	Cite No.1	U.S. Patent Docu	ment Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document  MM-DD-YYYY		
	1	2004063644			April 1, 2004		
	2	2002168360			November 14, 2002		
	3	2004092454			May 13, 2004		
==							

				FORE	IGN PATENT DOCUMEN	ITS		
Examiner		Foreign Patent Document  Kind Code <sup>5</sup>		Name of Patentee or Applicant of	Date of Publication of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant		
Initials*	Cite No.1	Office <sup>3</sup>	Number <sup>4</sup>	(if known)	Cited Document	MM-DD-YYYY	Figures Appear	T <sup>6</sup>
	4	DE	10063173		Merck Patent GmbH	June 20, 2002		Equv to cite 1
	5	wo	02070007		Medimmune Inc.	September 12, 2002		Equv to cite 2
	6	DE	19933173		Merck Patent GmbH	January 18,2001		
	7	wo	02074730		Merck Patent GmbH	September 26, 2002		Equv to cite 3

	Date
--	------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark

<sup>1</sup> Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.